资料显示，上海陆家嘴金融贸易区开发股份有限公司位于上海浦东东育路227弄6号前滩世贸中心(二 期)D栋18-21楼，成立日期1994年12月31日，上市日期1993年6月28日，公司主营业务涉及房地产租赁、 房产销售和物业管理。主营业务收入构成为：房地产88.01%，信托6.25%，其他3.27%，证券2.46%。 陆家嘴所属申万行业为：房地产-房地产开发-商业地产。所属概念板块包括：券商相关、园区开发、沪 自贸区、创投、上海国资等。 1月5日，陆家嘴盘中上涨2.02%，截至13:15，报8.07元/股，成交5458.21万元，换手率0.22%，总市值 406.34亿元。 资金流向方面，主力资金净流出95.72万元，特大单买入549.37万元，占比10.07%，卖出313.66万元，占 比5.75%；大单买入768.78万元，占比14.08%，卖出1100.21万元，占比20.16%。 陆家嘴今年以来股价涨2.02%，近5个交易日涨1.38%，近20日跌0.09%，近60日跌6.46%。 分红方面，陆家嘴A股上市后累计派现179.39亿元。近三年，累计派现21.66亿元。 机构持仓方面，截止2025年9月30 ...

Group 1 - The core viewpoint of the news is that Huayin Securities has shown a positive stock performance with a 2.02% increase on January 5, 2025, and a total market capitalization of 42.228 billion yuan [1] - As of September 30, 2025, Huayin Securities reported a total revenue of 1.2 billion yuan, representing a year-on-year growth of 18.08%, and a net profit attributable to shareholders of 440 million yuan, reflecting a 45.66% increase [2] - The company has distributed a total of 891 million yuan in dividends since its A-share listing, with 259 million yuan distributed over the past three years [3] Group 2 - The main business segments of Huayin Securities include wealth management (60.28%), proprietary trading (26.39%), other businesses (11.54%), investment banking (0.98%), and asset management (0.81%) [1] - As of September 30, 2025, the number of shareholders decreased by 5.46% to 52,800, while the average circulating shares per person increased by 5.78% to 51,138 shares [2] - The top ten circulating shareholders include various ETFs, with notable increases in holdings by Guotai CSI All-Index Securities Company ETF and Hong Kong Central Clearing Limited [3]

Core Viewpoint - Kangchen Pharmaceutical's stock price has shown a slight increase of 2.01% this year, but has experienced a decline of 9.81% over the past 20 days and 22.69% over the past 60 days, indicating volatility in its stock performance [2]. Group 1: Stock Performance - As of January 5, Kangchen Pharmaceutical's stock price reached 40.55 CNY per share, with a trading volume of 30.14 million CNY and a turnover rate of 0.47%, resulting in a total market capitalization of 6.448 billion CNY [1]. - The stock has increased by 2.01% year-to-date, with a minor increase of 0.22% over the last five trading days, while it has seen significant declines of 9.81% over the last 20 days and 22.69% over the last 60 days [2]. Group 2: Company Overview - Kangchen Pharmaceutical, established on September 3, 2003, and listed on August 27, 2018, is located in Beijing and focuses on innovative drug research and development, integrating R&D, production, and sales [2]. - The company's main business revenue is derived from Suling (70.77%), Salmon Calcitonin (29.15%), and other sources (0.09%) [2]. - The company operates within the pharmaceutical and biotechnology sector, specifically in the sub-sector of other biological products, and is associated with concepts such as monkeypox, biopharmaceuticals, innovative drugs, venture capital, and small-cap stocks [2]. Group 3: Financial Performance - For the period from January to September 2025, Kangchen Pharmaceutical reported a revenue of 692 million CNY, reflecting a year-on-year growth of 7.10%, and a net profit attributable to shareholders of 128 million CNY, which is a 13.19% increase compared to the previous year [2]. - Since its A-share listing, the company has distributed a total of 437 million CNY in dividends, with 175 million CNY distributed over the past three years [3]. Group 4: Shareholder Information - As of September 30, 2025, the number of shareholders for Kangchen Pharmaceutical reached 10,700, an increase of 7.18% from the previous period, with an average of 14,806 circulating shares per shareholder, a decrease of 6.12% [2]. - Notable new institutional shareholders include Qianhai Kaiyuan HuGangShen Advantage Selection Mixed A (holding 1.7445 million shares), Qianhai Kaiyuan China Scarce Asset Mixed A (holding 1.6075 million shares), and others, while several previous major shareholders have exited the top ten list [3].

1月5日，黑牡丹（维权）盘中上涨2.03%，截至09:35，报8.56元/股，成交685.54万元，换手率0.08%， 总市值88.34亿元。 资金流向方面，主力资金净流入3.67万元，大单买入207.35万元，占比30.25%，卖出203.68万元，占比 29.71%。 黑牡丹今年以来股价涨2.03%，近5个交易日跌4.89%，近20日跌10.65%，近60日涨13.08%。 资料显示，黑牡丹(集团)股份有限公司位于江苏省常州市新北区长江北路562号高铁新城创智大厦，成 立日期1993年5月28日，上市日期2002年6月18日，公司主营业务涉及城镇化建设业务、纺织服装业务和 产业投资业务。主营业务收入构成为：工程施工46.67%，地产业务27.94%，纺织服装20.86%，其他 3.52%，土地前期开发1.02%。 截至9月30日，黑牡丹股东户数2.78万，较上期减少13.97%；人均流通股37136股，较上期增加16.24%。 2025年1月-9月，黑牡丹实现营业收入24.43亿元，同比增长34.79%；归母净利润6379.21万元，同比减少 19.62%。 分红方面，黑牡丹A股上市后累计派现27.20亿 ...

关关关关关注注注注注投投投投投资资资资资界界界界界视视视视视频频频频频号号号号号 做做做做做创创创创创投投投投投圈圈圈圈圈最最最最最靓靓靓靓靓的的的的的仔仔仔仔仔 ...

Group 1 - The core point of the article highlights that Lushin Venture Capital has achieved a record trading volume of 2.716 billion RMB, marking the highest since its listing [2] - The latest stock price of Lushin Venture Capital has increased by 0.09%, with a turnover rate of 14.60% [2] - The trading volume on the previous trading day was only 52 million RMB, indicating a significant increase in investor interest [2] Group 2 - Lushin Venture Capital Group Co., Ltd. was established on November 20, 1993, with a registered capital of 744.359294 million RMB [2]

Group 1 - The core viewpoint of the news is that Jinfa Technology has shown significant stock performance, with a year-to-date increase of 127.58% and a recent trading volume indicating active market participation [1] - As of September 30, 2025, Jinfa Technology reported a revenue of 49.616 billion yuan, representing a year-on-year growth of 22.62%, and a net profit attributable to shareholders of 1.065 billion yuan, up 55.86% year-on-year [2] - The company has a diverse revenue structure, with modified plastics accounting for 52.07% of total revenue, followed by trading products at 20.65%, green petrochemical products at 18.85%, new materials at 6.29%, and medical health products at 1.48% [1] Group 2 - Jinfa Technology has a total market capitalization of 51.221 billion yuan, with a trading volume of 1.171 billion yuan and a turnover rate of 2.33% as of December 30 [1] - The company has seen an increase in shareholder accounts, reaching 395,400, which is a 94.23% increase compared to the previous period, while the average circulating shares per person decreased by 47.77% to 6,662 shares [2] - The company has distributed a total of 6.740 billion yuan in dividends since its A-share listing, with 1.136 billion yuan distributed in the last three years [3]

截至今日（12月29日）收盘，上证指数报收3965.28点，上涨0.04%；深证成指收于13537.10点，下跌 0.49%。创业板指下跌0.66%；科创50指数上涨0.04%。 声明： 不含未开板新股，今日可交易A股中，上涨个股有1995只，占比36.57%，下跌个股有3332只。其中，收 盘封死涨停的有88只，跌停股有26只。另外，30股封板未遂，整体封板率为74.58%。 责编：周莎 据证券时报·数据宝统计，以所属行业来看，涨停个股居前的行业有基础化工、机械设备、建筑装饰， 分别为12股、11股、8股。 从封单力度来看，锋龙股份、恒大高新、冀凯股份力度较大，分别为49.73%、13.06%、11%。 | | | | 12月29日涨停封单资金居前的个股 | | | --- | --- | --- | --- | --- | | 代码 | 名称 | 涨停封单额 | 涨停板 | 涨停原因 | | | | (亿元) | 情況 | | | 002931 | 锋龙股份 | 26.22 | 3连板 | 优必选拟入主+机器人 | | 002202 | 全风科技 | 5.33 | 首板 | 储能突破+风电龙头+绿氢氨醇 ...

12月29日，电子城盘中上涨2.01%，截至13:37，报5.57元/股，成交8089.49万元，换手率1.32%，总市值 62.31亿元。 资金流向方面，主力资金净流出538.53万元，特大单买入116.39万元，占比1.44%，卖出220.67万元，占 比2.73%；大单买入790.94万元，占比9.78%，卖出1225.19万元，占比15.15%。 电子城今年以来股价涨27.17%，近5个交易日跌1.24%，近20日涨1.46%，近60日跌2.45%。 今年以来电子城已经7次登上龙虎榜，最近一次登上龙虎榜为9月23日，当日龙虎榜净买入-4764.60万 元；买入总计2877.00万元 ，占总成交额比6.07%；卖出总计7641.60万元 ，占总成交额比16.12%。 资料显示，北京电子城高科技集团股份有限公司位于北京市朝阳区酒仙桥路6号院5号楼15层-19层，成 立日期1986年12月24日，上市日期1993年5月24日，公司主营业务涉及园区地产开发与销售、新型科技 服务(园区物业出租与管理)、广告传媒和产品销售。主营业务收入构成为：新型科技服务73.23%，地产 销售23.70%，广告传媒3.06%， ...

资料显示，中国石油集团资本股份有限公司位于北京市西城区金融大街一号金亚光大厦B座22层，成立 日期1996年10月11日，上市日期1996年10月22日，公司主营业务涉及涵盖财务公司、银行、金融租赁、 信托、保险、保险经纪、证券等多项金融业务的全方位综合性金融业务。主营业务收入构成为：利息收 入88.54%，已赚保费4.48%，手续费及佣金收入4.47%，其他业务2.51%。 中油资本所属申万行业为：非银金融-多元金融-金融控股。所属概念板块包括：碳中和、央企改革、创 投、氢能源、新疆振兴等。 资金流向方面，主力资金净流出1946.32万元，特大单买入5210.07万元，占比6.57%，卖出5641.37万 元，占比7.11%；大单买入1.64亿元，占比20.66%，卖出1.79亿元，占比22.57%。 中油资本今年以来股价涨43.81%，近5个交易日涨5.75%，近20日涨5.87%，近60日跌5.98%。 今年以来中油资本已经8次登上龙虎榜，最近一次登上龙虎榜为9月2日，当日龙虎榜净买入-1.84亿元； 买入总计7.16亿元 ，占总成交额比13.60%；卖出总计8.99亿元 ，占总成交额比17.09%。 ...